tradmap

MGNX Financials MACROGENICS INC

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has grown 7.3% per year over the past 5 years.
  • Operating margin has expanded, at -48.7% in the latest year.

Financial health

  • Operating income covered interest expense -8.6× in the latest year.
  • The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
Revenue & net income
-$202M -$22M $158M $0 2011 2013 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
-286% -93% 100% 0% 2011 2013 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Return on equity & assets (ROE / ROA)
-102% -43% 16% 0% 2011 2013 2015 2017 2019 2021 2023 2025
ROEROA
Free cash flow (CFO − capex)
-$178M -$86M $6M $0 2011 2013 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $110M $220M 2011 2013 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$153M $11M $174M $0 2011 2013 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MROEROAFCFTotal debtCash
2025 $150M -$74620 100.0% -48.7% -0.1% -0.0% -$83M — $57M
2024 $150M -$66966 99.4% -73.7% -0.1% -0.0% -$72M — $183M
2023 $59M -$9058 98.9% -286.4% -0.0% -0.0% -$80M — $101M
2022 $152M -$120M 97.8% -79.9% -84.3% -42.7% -$91M — $109M
2021 $77M -$202M 96.6% -261.9% -84.3% -60.3% -$150M — $123M
2020 $105M -$130M 100.0% -125.0% -43.8% -34.3% -$118M — $181M
2019 $64M -$152M 100.0% -276.0% -65.8% -48.6% -$139M — $126M
2018 $60M -$171M 0.0% -284.8% -70.6% -51.6% -$178M — $220M
2017 $158M -$20M 0.0% -14.0% -6.6% -5.2% -$15M — $212M
2016 $92M -$59M 0.0% -65.3% -21.8% -18.8% — — $84M
2015 $101M -$20M 0.0% -20.0% -6.4% -5.6% — — $196M
2014 $48M -$38M 0.0% -80.2% -31.6% -22.0% — — $158M
2013 $58M -$261000 0.0% 0.6% -0.3% -0.2% -$17M — $116M
2012 $64M $8M 0.0% 12.9% -101.5% 15.6% -$8M — $48M
2011 $57M $7M 0.0% 9.2% -38.4% — $6M — $55M

Valuation over time

How the market has priced MGNX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / sales (P/S)
0.0 9.7 19.4 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/S

Frequently asked questions

Is MGNX growing its revenue and profit?

Over the past 5 years, MACROGENICS INC's revenue has grown 7.3% per year. These are computed facts, not advice.

How much debt does MGNX have?

As of FY2025, MACROGENICS INC reported — of total debt against $57M of cash; operating income covered interest expense -8.6×.

What is MGNX's profit margin?

In FY2025, gross margin was 100.0%, operating margin -48.7%, and net margin -0.0%.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.